Fryer Ryan M, Rakestraw Pamela A, Nakane Masaki, Dixon Doug, Banfor Patricia N, Koch Kristin A, Wu-Wong J Ruth, Reinhart Glenn A
Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6119, USA.
Nephron Physiol. 2007;106(4):p76-81. doi: 10.1159/000104875. Epub 2007 Jul 2.
BACKGROUND/AIMS: Vitamin D receptor activators (VDRAs) may suppress renin expression and VDR-mediated renin inhibitors may offer a novel mechanism to control the RAS.
We delineated the effects of paricalcitol and calcitriol on PTH, renin, and iCa(2+) in C57/BL6 mice administered vehicle, paricalcitol, or calcitriol (0.01, 0.03, 0.10, 0.33, 1.0 microg/kg s.c.) 3 days/week for 9 days.
Paricalcitol produced PTH suppression from 0.03 to 1.0 microg/kg (values between 9.7 +/- 3.3 and 20.7 +/- 4.7 pg/ml; vehicle = 88.0 +/- 16.9) and elicited dose-dependent reductions in renin/GAPDH expression at 0.33 and 1.0 microg/kg (0.037 +/- 0.002, 0.027 +/- 0.003; vehicle = 0.054 +/- 0.003) but produced no increases iCa(2+) at any dose tested. Calcitrol produced PTH suppression at all doses tested (between 6.4 +/- 1.2 and 29.5 +/- 17.2 pg/ml) and renin suppression at 0.10, 0.33, and 1.0 microg/kg (0.029 +/- 0.002, 0.031 +/- 0.003, and 0.038 +/- 0.02). However, at 0.33 and 1.0 mg/kg, calcitriol produced increases iCa(2+) (1.31 +/- 0.03 and 1.48 +/- 0.02 mmol/l; vehicle = 1.23 +/- 0.02 mmol/l).
Paricalcitol produces significant, dose-dependent suppression of renin expression in the absence of hypercalcemia at doses 10-fold above those necessary for PTH suppression. Calcitriol also produced suppression of renin at doses at least 10-fold above those required for PTH suppression, but increases in iCa(2+) were observed at doses only 3-fold above those necessary to elicit renin suppression.
背景/目的:维生素D受体激活剂(VDRAs)可能会抑制肾素表达,且VDR介导的肾素抑制剂可能为控制肾素-血管紧张素系统(RAS)提供一种新机制。
我们对C57/BL6小鼠皮下注射溶媒、帕立骨化醇或骨化三醇(0.01、0.03、0.10、0.33、1.0微克/千克),每周3天,共9天,然后描绘帕立骨化醇和骨化三醇对甲状旁腺激素(PTH)、肾素和离子钙(iCa²⁺)的影响。
帕立骨化醇在剂量为0.03至1.0微克/千克时可抑制PTH(值在9.7±3.3至20.7±4.7皮克/毫升之间;溶媒组=88.0±16.9),并在剂量为0.33和1.0微克/千克时引起肾素/甘油醛-3-磷酸脱氢酶(GAPDH)表达呈剂量依赖性降低(0.037±0.002,0.027±0.003;溶媒组=0.054±0.003),但在任何测试剂量下均未使iCa²⁺升高。骨化三醇在所有测试剂量下均能抑制PTH(在6.4±1.2至29.5±17.2皮克/毫升之间),并在剂量为0.10、0.33和1.0微克/千克时抑制肾素(0.029±0.002,0.031±0.003,0.038±0.02)。然而,在剂量为0.33和1.0毫克/千克时,骨化三醇使iCa²⁺升高(1.31±0.03和1.48±0.02毫摩尔/升;溶媒组=1.23±0.02毫摩尔/升)。
帕立骨化醇在高于抑制PTH所需剂量10倍的情况下,在无高钙血症时可显著、剂量依赖性地抑制肾素表达。骨化三醇在高于抑制PTH所需剂量至少10倍时也能抑制肾素,但在仅高于引起肾素抑制所需剂量3倍时就观察到iCa²⁺升高。